Weight reduction: In the phase 2 trial, cagrilintide 4.5 mg weekly produced approximately 10.8% body weight loss over 26 weeks versus 3.0% with placebo [4]
Medical professionals understand that theres an emotional facet at play (which was the factor contributing to your weight gain.) With this food addiction, health professionals will provide alternatives to make the transition smooth and supplement what youll lose
Furthermore, the safety, and PK and PD profiles, of tirzepatide in Chinese patients were consistent with those previously reported in global and other Asian populations [4,5,6,7,8,9,10, 15], which provided evidence that tirzepatide can potentially provide improvements in glycemic control and reduce body weight in patients with T2D
It contains Semaglutide base, which is FDA-approved, ensuring safety and reliability for users